PLATO Primary Efficacy End Point: CV Death, MI, or Stroke

1
(No Transcript)
2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
PLATO Primary Efficacy End Point CV Death, MI,
or Stroke
6
Ticagrelor PEGASUS Study Design
7
Cangrelor CHAMPION PHOENIX Study Design
8
CHAMPION PHOENIX Primary Efficacy Outcomes at 48
Hours, MITT
9
(No Transcript)
10
ESC NSTEMI ACS Guidelines
11
Ticagrelor ATLANTIC Study Design
12
Rivaroxaban ATLAS ACS 2-TIMI 51 Study Design
13
ATLAS ACS 2-TIMI 51
14
ANTARCTIC Study Design
15
Other Points to Consider
16
Abbreviations (cont)
17
Abbreviations (cont)
18
Abbreviations (cont)
19
References
20
References (cont)
21
References (cont)
22
References (cont)